Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 2/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 4/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.42 |
| ▸ | CCR1 | P32246 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | LSS | P48449 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6136341 | 0.95 | MTOR (0.53) | MTORTRPV1ESR1ESR2ROCK2 | |
| SCHEMBL6136177 | 0.92 | MTOR (0.49) | MTORTRPV1ESR1ESR2CCR1 | |
| SCHEMBL6136147 | 0.91 | MTOR (0.61) | MTORTRPV1ESR1ESR2EGFR | |
| SCHEMBL6136139 | 0.89 | MTOR (0.47) | MTORTRPV1ESR1ESR2CCR1 | |
| SCHEMBL6136358 | 0.89 | TRPV1 (0.43) | TRPV1ESR1ESR2CCR1ROCK2 | |
| SCHEMBL6136057 | 0.85 | NPY5R (0.40) | MTORTRPV1ESR1ESR2TSHR | |
| SCHEMBL6136025 | 0.84 | TRPV1 (0.53) | MTORTRPV1ESR1ESR2 | |
| SCHEMBL6136065 | 0.84 | TRPV1 (0.47) | MTORTRPV1ESR1ESR2ROCK2 | |
| SCHEMBL6136280 | 0.82 | ERCC1 (0.49) | MTORTRPV1ESR1ESR2LSS | |
| SCHEMBL6136144 | 0.81 | TRPV1 (0.44) | MTORTRPV1ESR1ESR2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0895989-B1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | LILLY CO ELI (US) | 2005-05-18 | — | — | EP | claimed |
| US-6509356-B1 | Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound | ELI LILLY AND COMPANY | 2003-01-21 | — | — | US | claimed |
| EP-0895989-A1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | ELI LILLY AND COMPANY (US) | 1999-02-10 | — | — | EP | claimed |
| EP-0895989-B1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | LILLY CO ELI (US) | 2005-05-18 | — | — | EP | disclosed |
| US-6509356-B1 | Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound | ELI LILLY AND COMPANY | 2003-01-21 | — | — | US | disclosed |
| EP-0895989-A1 | 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity | ELI LILLY AND COMPANY (US) | 1999-02-10 | — | — | EP | disclosed |